1. Skip to Menu
  2. Skip to Content
  3. Skip to Footer

Press releases

SourceData and BioStudies bring open data sharing to EMBO Press

 

Heidelberg, Hinxton, 9 December 2018 – SourceData from EMBO is an open platform that makes the data in research papers directly searchable. SourceData describes the contents of figures from scientific articles in a standardized, machine-readable format, allowing articles to be searched and interlinked using their data content. In collaboration with BioStudies from EMBL-EBI, a database that aggregates the data files linked to a specific publication or project, SourceData now offers an integrated workflow to make published data openly accessible and easy to find.

Read more...

Towards a treatment for gluten intolerance

 

While mutations of the ion-channel CFTR cause cystic fibrosis, its inhibition may serve as a target for addressing celiac disease

 

Heidelberg, 30 November 2018 - Celiac disease is a severe autoimmune disorder of the intestine. It occurs when people develop sensitivity to gluten, a substance found in wheat, rye, and barley. An international research team from Italy and France has now uncovered a new molecular player in the development of gluten intolerance. Their discovery, published in The EMBO Journal, suggests potential targets for the development of therapeutic approaches for the disease.

Read more...

EMBO welcomes twenty-six new Young Investigators

 

Heidelberg, 20 November 2018 – EMBO has selected 26 life science researchers within their first four years as group leaders to become EMBO Young Investigators. They join an active network of 102 current and 314 past Young Investigators and will receive support from EMBO during the foundation of their first independent laboratory.

Read more...

A gene required for addictive behavior

 

Researchers show that mice lacking the Maged1 gene are unable to acquire cocaine addiction

 

Heidelberg, 12 July 2018 - Cocaine can have a devastating effect on people. It directly stimulates the brain’s reward center, and, more importantly, induces long-term changes to the reward circuitry that are responsible for addictive behaviors. Alban de Kerchove d'Exaerde from the Université Libre de Bruxelles, Belgium, and his colleagues have now uncovered that a gene called Maged1 plays a crucial role in controlling these pathological changes. This finding, published today in EMBO Reports, opens the door to further investigations into the molecular mechanisms underlying addiction-associated adaptations in the brain.

Read more...

EMBO welcomes Montenegro as its 30th member

 

Heidelberg, 30 May 2018 – EMBO is pleased to announce that Montenegro has joined its intergovernmental funding body, the European Molecular Biology Conference (EMBC). Montenegro is the 30th country to become part of the EMBC, and will now be able to benefit from the support EMBO offers to talented life science researchers at all career stages.

Read more...

EMBO Gold Medal 2018 awarded to Marek Basler and Melina Schuh

 

Heidelberg, 16 May 2018 – The recipients of the EMBO Gold Medal 2018 are Czech microbiologist Marek Basler and German biochemist Melina Schuh.

Read more...

62 life scientists elected as EMBO Members

 

Heidelberg, 14 May 2018 – EMBO announces today that 62 outstanding life scientists have been elected to its membership, joining a group of more than 1800 of the best researchers in Europe and around the world.

Read more...

Tailoring blood cells in the laboratory

 

Researchers are a step closer to growing blood cells customized to the special needs of transfusion patients with rare blood groups

 

Heidelberg, 26 April 2018 − For some blood transfusion patients, it is particularly difficult to find a compatible blood donor. Growing matching blood cells in the laboratory has long been an overarching goal of scientists for these patients. Research from Ashley Toye and colleagues at the University of Bristol, UK, and NHS Blood and Transplant has brought this vision one step closer to reality. The research is published today in EMBO Molecular Medicine.

Read more...

How to hijack degrading complexes to put cancer cells asleep

 

Researchers uncover an alternative path of how the breast cancer drug palbociclib drives malignant cells into senescence

 

Heidelberg, 23 April 2018 - Palbociclib is a drug used for the treatment of advanced estrogen-receptor-positive breast cancer. It induces cell cycle arrest and senescence, an irreversible resting state marking these ‘out-of-order’ cells to be cleared by the immune system. Notably, the mechanistic details of how palbociclib drives cancer cells into senescence are largely unknown to date. Researchers at the Universities of Dundee and Newcastle and their colleagues now investigated the drug’s mode of action in more detail and uncovered the proteasome, a cellular degradation machinery vital for the control of cell proliferation, as its yet unknown target. Their discovery could potentially help expand palbociclib-based breast cancer treatments and identify patients that would profit most from this medication. The research was published in The EMBO Journal.

Read more...

A new blood test useful to detect people at risk of developing Alzheimer’s disease

 

Heidelberg, 6 April 2018 −There is as yet no cure for Alzheimer’s disease. It is often argued that progress in drug research has been hampered by the fact that the disease can only be diagnosed when it is too late for an effective intervention. Alzheimer’s disease is thought to begin long before patients show typical symptoms like memory loss. Scientists have now developed a blood test for Alzheimer’s disease and found that it can detect early indicators of the disease long before the first symptoms appear in patients. The blood test would thus offer an opportunity to identify those at risk and may thereby open the door to new avenues in drug discovery. The research is published today in EMBO Molecular Medicine.

Read more...

Not-for-profit publishers partner to launch new research journal Life Science Alliance

 

EMBO Press, Rockefeller University Press and Cold Spring Harbor Laboratory Press join forces to empower authors to publish new research more efficiently

 

Heidelberg, New York, and Cold Spring Harbor, 3 April 2018 EMBO Press, Rockefeller University Press, and Cold Spring Harbor Laboratory Press today announce the launch of Life Science Alliance, a new global, open access, editorially independent, peer-reviewed journal committed to rapid, fair and transparent publication of valuable research from across the life sciences. Manuscripts can be submitted to Life Science Alliance directly or by seamless transfer without reformatting from nine partner journals: The EMBO Journal, EMBO Reports, Molecular Systems Biology, EMBO Molecular Medicine, Journal of Cell Biology, Journal of Experimental Medicine, Journal of General Physiology, Genes & Development, and Genome Research.

Read more...

Frauke Melchior receives the 2018 FEBS | EMBO Women in Science Award

 

Heidelberg, 20 February 2018 – EMBO and the Federation of European Biochemical Societies (FEBS) announce Frauke Melchior from the Center for Molecular Biology (ZMBH) at Heidelberg University, Germany, as the recipient of the 2018 FEBS | EMBO Women in Science Award.

Read more...

Contact

This email address is being protected from spambots. You need JavaScript enabled to view it.

 


Tilmann KießlingTilmann Kießling
Head, Communications
T. + 49 160 9019 3839